Pan-RAF Inhibitor (now JZP815)

Sold to Jazz Pharmaceutical, July 2019




Phase 1

Phase 2

Phase 3

Upcoming Milestones


Pan-RAF Inhibitor


Sold to Jazz Pharmaceuticals

Pan-RAF inhibitor programme sold to Jazz Pharmaceuticals

On 10 July 2019, Redx Pharma announced that it had signed a definitive agreement with Jazz Pharmaceuticals under which Jazz acquired Redx’s pan-RAF inhibitor programme for the potential treatment of RAF and RAS mutant tumours. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities.

Under the terms of the agreement, Jazz paid Redx an upfront payment of $3.5 million in cash for all rights, title and interest relating to Redx’s proprietary pan-RAF inhibitor programme, including all related patents. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments from Jazz, $3 million of which was earned in September 2021 following the initiation of IND-enabling studies, and a further $5 million was earned in June 2022 with the clearance of IND application. Redx is also eligible for incremental tiered royalties in mid-single digit percentages, based on any future net sales. As part of a separate collaboration agreement, signed in parallel, Jazz pays Redx to perform research and preclinical development services with the goal of completing IND-enabling studies.

Read the press release

We’re excited to advance JZP815, a precision pan-RAF inhibitor with a differentiated mechanism of action, into a clinical trial programme. JZP815 may represent a significant advancement in the pan-RAF inhibitor class by not inducing paradoxical pathway activation that can stimulate the growth of certain cancers. The JZP815 programme exemplifies our continued progress in expanding our early-stage oncology pipeline, and in developing therapies with the potential to address unmet patient need. Redx has an exceptional team of research and development scientists and together we have formed an outstanding collaboration, leveraging the strengths of both companies.

Robert Iannone

M.D., M.S.C.E., Executive Vice President, Research and development, Jazz Pharmaceuticals

Pan-Raf inhibitor programme: Overcoming drug resistance mechanisms

Our Pan-RAF inhibitor programme aims to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs.

Mutations leading to uncontrolled signalling via the RAS-RAF-MAPK pathway are seen in over one third of all cancers. The RAF kinases (A-RAF, B-RAF and C-RAF) are an integral part of this pathway, with B-RAF mutations commonly seen in the clinic. Although most B-RAFV600E/K mutant skin cancers are initially sensitive to approved B-RAF selective drugs, treatment resistance often leads to disease progression. Moreover, B-RAFV600E mutant colorectal cancers are surprisingly insensitive to these B-RAF selective agents due to the functions of other RAF family members. Importantly, B-RAF selective therapies fail to show clinical benefit against the more prevalent RAS-mutated tumours.

To overcome these resistance mechanisms our scientists are developing a Pan-RAF inhibitor programme. Our lead chemical series has demonstrated monotherapy in vivo efficacy in a B-RAFV600E mutant colorectal cancer xenograft model, where approved B-RAF selective drugs are ineffective as monotherapy. In addition, this series shows monotherapy in vivo efficacy in a RAS-mutant colorectal cancer xenograft model.